DHCR24 predicts poor clinicopathological features of patients with bladder cancer: A STROBE-compliant study. Issue 39 (September 2018)

• Record Type: Journal Article
• Authors: Liu, Xiao-Ping; Yin, Xiao-Hong; Meng, Xiang-Yu; Yan, Xin-Hui; Cao, Yue; Zeng, Xian-Tao; Wang, Xing-Huan
• Other Names: Mancini. Vito section editor.
• Is Part Of: Medicine. Volume 97:Issue 39(2018)
• Publication Date: 2018-09
• Subjects: bladder cancer -- DHCR24 -- prognostic relevance; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000011830
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: To investigate the prognostic value of DHCR24 for patients with bladder cancer (BC). We used public bladder cancer microarray studies to evaluate the expression of DHCR24 between normal bladder tissues and BC cells, to investigate the relationship between the expression of DHCR24 and the clinical features of BC patients. Survival analysis was performed to investigate the correlation between DHCR24 expression and the survivals of BC patients. Gene set enrichment analysis was conducted to identify relevant mechanisms. The results showed that DHCR24 was up-regulated in BC cells compared with that in normal bladder tissues ( P = .0389). Results of chi-square test suggested that BC patients in DHCR24 low expression group were proved to have better clinical characteristics (including tumor grade, disease progression, T staging, and N staging) as compared with those in DHCR24 low expression group ( P < .0001, P = .002, P = .005, and P = .002, respectively). BC patients in DHCR24 low expression group were associated with better cancer-specific survival and overall survival ( P < .0001 and P = .0008, respectively). DHCR24 might promote the proliferation of BC cells through several oncogenesis-associated biological processes (estrogen response, heme metabolism, P53 pathway, cholesterol homeostasis, mTORC1 signaling, peroxisome, xenobiotic metabolism, glycolysis, and protein secretion). Thus, DHCR24 might be a therapeutic target for patients with BC.